Biotech Values

[dewophile]

Re GSK upcoming HBV data

The abstract title mentions that interferon did reduce relapse, but we have to wait for the presentation to find out by how much. As a reminder 28/29% of patients in both groups (on nukes and not on nukes) were undetectable and had no surface antigen at end of treatment in the monotherapy trial, but this was down to 6-10% a few months post therapy (16 and 25% of those w low starting HBSAg)

https://www.gsk.com/en-gb/media/press-releases/gsk-presents-scientific-advances-to-improve-patient-outcomes-at-the-american-association-for-the-study-of-liver-diseases-the-liver-meeting-2023/

Pegylated interferon reduces relapses following bepirovirsen treatment in participants with chronic hepatitis B virus infection on nucleos(t)ide analogues: end of study results from the Phase 2b B-Together study